000143636 001__ 143636
000143636 005__ 20240229112601.0
000143636 0247_ $$2doi$$a10.1001/jama.2019.4755
000143636 0247_ $$2pmid$$apmid:31063574
000143636 0247_ $$2ISSN$$a0002-9955
000143636 0247_ $$2ISSN$$a0098-7484
000143636 0247_ $$2ISSN$$a0254-9077
000143636 0247_ $$2ISSN$$a1538-3598
000143636 0247_ $$2ISSN$$a2376-8118
000143636 0247_ $$2altmetric$$aaltmetric:60036129
000143636 037__ $$aDKFZ-2019-01213
000143636 041__ $$aeng
000143636 082__ $$a610
000143636 1001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b0$$eFirst author$$udkfz
000143636 245__ $$aEffect of a Single Aspirin Dose Prior to Fecal Immunochemical Testing on Test Sensitivity for Detecting Advanced Colorectal Neoplasms: A Randomized Clinical Trial.
000143636 260__ $$aChicago, Ill.$$bAmerican Medical Association$$c2019
000143636 3367_ $$2DRIVER$$aarticle
000143636 3367_ $$2DataCite$$aOutput Types/Journal article
000143636 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1562075602_20102
000143636 3367_ $$2BibTeX$$aARTICLE
000143636 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143636 3367_ $$00$$2EndNote$$aJournal Article
000143636 520__ $$aFecal immunochemical tests for hemoglobin are widely used for colorectal cancer (CRC) screening. Observational studies suggested that sensitivity of fecal immunochemical tests for detecting advanced neoplasms could be increased by acetylsalicylic acid (aspirin), especially among men.To evaluate the potential to increase sensitivity of fecal immunochemical tests by administering a single 300-mg oral aspirin dose 2 days before stool sampling.A randomized, placebo-controlled, double-blind trial was conducted in 14 gastroenterology practices and 4 hospitals in Germany, and included 2422 men and women aged 40 to 80 years scheduled for colonoscopy, with no recent use of aspirin or other drugs with antithrombotic effects (enrollment from June 2013 to November 2016, and final follow-up January 27, 2017).Administration of a single tablet containing 300 mg of aspirin (n = 1208) or placebo (n = 1214) 2 days before fecal sampling for fecal immunochemical test.The primary outcome was sensitivity of a quantitative fecal immunochemical test at 2 predefined cutoffs (10.2 and 17-μg Hb/g stool) for detecting advanced neoplasms (colorectal cancer or advanced adenoma).Among 2422 randomized patients (mean [SD] age, 59.6 [7.9] years; 1219, 50%, men), 2134 were included in the analysis (78% for primary screening colonoscopy, 22% for diagnostic colonoscopy). Advanced neoplasms were identified in 224 participants (10.5%), including 8 participants (0.4%) with CRC and 216 participants (10.1%) with advanced adenoma. Sensitivity was 40.2% in the aspirin group and 30.4% in the placebo group (difference 9.8%, 95% CI, -3.1% to 22.2%, P = .14) at cutoff 10.2-μg Hb/g stool and 28.6% in the aspirin and 22.5% in the placebo group (difference 6.0%, 95% CI, -5.7% to 17.5%, P = .32) at cutoff 17-μg Hb/g stool.Among adults aged 40 to 80 years not using aspirin or other antithrombotic medications, administration of a single dose of oral aspirin prior to fecal immunochemical testing, compared with placebo, did not significantly increase test sensitivity for detecting advanced colorectal neoplasms at 2 predefined cutoffs of a quantitative fecal immunochemical test.Deutsches Register Klinischer Studien Identifier: DRKS00003252; EudraCT Identifier: 2011-005603-32/DE.
000143636 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000143636 588__ $$aDataset connected to CrossRef, PubMed,
000143636 7001_ $$0P:(DE-HGF)0$$aCalderazzo, Silvia$$b1
000143636 7001_ $$aSeufferlein, Thomas$$b2
000143636 7001_ $$aLudwig, Leopold$$b3
000143636 7001_ $$aDikopoulos, Nektarios$$b4
000143636 7001_ $$aMangold, Jörg$$b5
000143636 7001_ $$aBöck, Wolfgang$$b6
000143636 7001_ $$aStolz, Thomas$$b7
000143636 7001_ $$aEisenbach, Thomas$$b8
000143636 7001_ $$aBlock, Thomas$$b9
000143636 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b10$$udkfz
000143636 7001_ $$aCzock, David$$b11
000143636 7001_ $$0P:(DE-He78)eabbefb821cdb73961a5adf967330b62$$aTikk, Kaja$$b12$$eLast author$$udkfz
000143636 773__ $$0PERI:(DE-600)2018410-4$$a10.1001/jama.2019.4755$$gVol. 321, no. 17, p. 1686 -$$n17$$p1686 - 1692$$tThe journal of the American Medical Association$$v321$$x0098-7484$$y2019
000143636 909CO $$ooai:inrepo02.dkfz.de:143636$$pVDB
000143636 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000143636 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000143636 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000143636 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)eabbefb821cdb73961a5adf967330b62$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000143636 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000143636 9141_ $$y2019
000143636 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143636 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143636 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJAMA-J AM MED ASSOC : 2017
000143636 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143636 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000143636 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000143636 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143636 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000143636 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143636 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143636 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143636 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000143636 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000143636 915__ $$0StatID:(DE-HGF)9940$$2StatID$$aIF >= 40$$bJAMA-J AM MED ASSOC : 2017
000143636 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000143636 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000143636 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x2
000143636 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x3
000143636 980__ $$ajournal
000143636 980__ $$aVDB
000143636 980__ $$aI:(DE-He78)C070-20160331
000143636 980__ $$aI:(DE-He78)C120-20160331
000143636 980__ $$aI:(DE-He78)C060-20160331
000143636 980__ $$aI:(DE-He78)L101-20160331
000143636 980__ $$aUNRESTRICTED